Business Context and Reporting Period
This Form 6-K filing by Novartis AG, dated September 8, 2026, reports an ad hoc announcement regarding the Phase III HARBOR study for delpacibart etedesiran (del-desiran) in the treatment of myotonic dystrophy type 1 (DM1). The filing also provides updates on the company's antibody oligonucleotide conjugate (AOC) pipeline and reaffirms long-term sales guidance.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the current period. The only financial metric disclosed is a strategic growth target:
- Sales Guidance: Novartis maintains a 5-6% five-year sales Compound Annual Growth Rate (CAGR) guidance for the period 2025-2030.
Material Changes and Clinical Developments
The primary material change reported is the outcome of the HARBOR clinical trial:
- HARBOR Study Outcome: The Phase III study for del-desiran in DM1 did not meet its primary endpoint of video hand opening time (vHOT) versus placebo.
- Secondary Findings: Evidence of clinical activity was observed in secondary endpoints and exploratory analyses. Safety findings were consistent with previously reported data.
- Pipeline Progress:
- DMD44: FDA granted priority review for delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy.
- FSHD: Novartis plans an FDA meeting for delpacibart braxlosiran (del-brax) based on positive Phase I/II biomarker data.
Guidance, Outlook, and Risks
Management Commentary: Novartis management acknowledged the challenge of developing therapies for complex diseases like DM1, stating that setbacks are part of scientific progress. The company remains committed to evaluating the full HARBOR dataset to determine the appropriate development path for del-desiran.
Outlook: The company continues to advance its neuromuscular pipeline and has reaffirmed its 5-6% sales CAGR guidance for 2025-2030.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks include uncertainties regarding clinical trial results, regulatory approvals, pricing pressures, patent protection, and macroeconomic factors. There is no guarantee that del-desiran, del-zota, or del-brax will be approved or commercially successful.
Investor Verification Checklist
- Verify the specific details of the secondary endpoints and exploratory analyses where clinical activity was observed in the HARBOR study.
- Monitor the timeline for Novartis's engagement with health authorities regarding the future development path of del-desiran.
- Track the FDA decision timeline for the priority review of delpacibart zotadirsen (del-zota) in DMD44.
- Confirm the date and agenda of the planned FDA meeting for delpacibart braxlosiran (del-brax) in FSHD.
- Review subsequent Form 20-F filings for updated financial performance and any adjustments to the 2025-2030 sales guidance.